文献速递乳腺PET

专用乳腺PET能否通过区分惰性与潜在侵袭性导管原位癌来减少过度诊断和过度治疗?

Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
PubMed 文献 · Eur Radiol · 2019-08-02

本研究回顾性分析两家医院2016年1月至2018年5月活检和手术前接受专用乳腺PET(dbPET)的139例纯导管原位癌(DCIS)病例,将1级和无粉刺的2级DCIS归为低风险,伴坏死的中级别或3级归为高风险。dbPET区分惰性与潜在侵袭性DCIS的敏感度为90%(95%CI 77-96%),特异度为92%(95%CI 84-97%)。作者认为代谢影像可能有助于识别可主动监测的惰性病变亚组。

要点

  • dbPET区分惰性与潜在侵袭性DCIS的敏感度为90%(95%CI 77-96%),特异度为92%(95%CI 84-97%)。
  • 139例纯DCIS中高风险50例、低风险89例;仅7例低风险病变dbPET阳性,5例潜在侵袭性病变未见FDG摄取(均在视野内)。
  • 作者认为dbPET可能区分无害与潜在危险的DCIS,支持对低级别DCIS女性行主动监测。

核心结论

  • 代谢影像可能有助于从潜在侵袭性DCIS中识别出惰性病变亚组,后者可能通过主动监测管理。

研究设计与样本

  • 经机构审查委员会批准后,回顾性分析西班牙卢戈Lucus Augusti大学医院和中国上海复旦大学附属肿瘤医院2016年1月至2018年5月活检和手术前接受dbPET的纯DCIS病例,共纳入139例手术确诊的纯DCIS。

关键影像表现/征象

  • 仅7例低风险病变dbPET阳性,5例潜在侵袭性病变未见FDG摄取,均在视野内。

诊断标准与关键数值

  • 1级和无粉刺的2级DCIS归为低风险,伴坏死的中级别或3级归为高风险。
  • dbPET区分惰性与潜在侵袭性DCIS的敏感度为90%(95%CI 77-96%),特异度为92%(95%CI 84-97%)。

临床应用与阅片要点

  • 作者认为dbPET可能区分无害与潜在危险的DCIS,支持对低级别DCIS女性行主动监测,降低手术切除时升级为浸润性癌的比例。
  • 正在进行的临床试验评估低风险DCIS患者能否通过主动监测安全处理,避免不必要的治疗且不影响同侧浸润性乳腺癌无病生存时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To analyze the utility of metabolic imaging, and specifically of dedicated breast positron emission tomography (dbPET) to differentiate between indolent and potentially aggressive ductal carcinoma in situ (DCIS).

METHODS: After institutional review board approval, we retrospectively reviewed the cases of pure DCIS who underwent dbPET before biopsy and surgery in Lucus Augusti Universitary Hospital (Lugo, Spain) and in Fudan Cancer Institute (Shanghai, China) between January 2016 and May 2018. Grade 1 and "non-comedo" grade 2 DCIS were considered low-risk disease, while intermediate-grade with necrosis or grade 3 cases were included in the high-risk group. DbPET sensitivity and specificity to differentiate between indolent and potentially aggressive DCIS were determined along with their respective 95% confidence intervals.

RESULTS: We enrolled 139 surgery-confirmed pure DCIS cases. Fifty were high-risk neoplasms and 89 low-risk DCIS. Only seven low-risk lesions were positive at dbPET and five of potentially aggressive neoplasms did not show FDG uptake, all included into the field of view (FOV). Sensitivity and specificity of dbPET to differentiate between indolent and potentially aggressive DCIS were 90% (95% CI, 77-96%) and 92% (95% CI, 84-97%), respectively.

CONCLUSION: Metabolic imaging could help to identify the subgroup of indolent lesions from those potentially aggressive ones that may be managed by active surveillance.

KEY POINTS: • Low- and high-grade DCIS likely arise from two distinct evolutionary paths and when low-grade lesions progress to invasive cancer, the tumor is frequently low grade and well differentiated. • Ongoing clinical trials evaluate whether patients with low-risk DCIS could be safely managed by an active surveillance approach, with avoidance of unnecessary treatments and without impact on ipsilateral invasive breast cancer free survival time. • Dedicated breast PET may differentiate harmless from potentially hazardous DCIS, supporting active surveillance for the management of those women with low-grade DCIS, decreasing the rate of the upgrade to invasive carcinoma at surgical excision.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Graña-López L, Herranz M, Domínguez-Prado I, et al. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ? Eur Radiol. 2019. PMID: 31375867. doi:10.1007/s00330-019-06356-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。